Introduction
Podophyllotoxin 1 (Figure 1 ) is the most abundant naturally occurring cyclolignan mainly isolated from podophyllum species and shows strong cytotoxic activity against various cancer cell lines by inhibiting microtubule assembly. [1] [2] [3] Podophyllotoxin is not a clinically useful anticancer drug because of its high toxicity; however, several semisynthetic derivatives, such as etoposide (2) (Figure 1 ), are clinically used chemotherapeutic agents
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Zi et al for a number of cancers, including small cell lung cancer, testicular carcinoma, lymphoma, and Kaposi's sarcoma. [4] [5] [6] Earlier reports indicated that the β-configuration at C-4 of podophyllotoxin scaffold is not favorable for tubulin polymerization inhibition activity. 7 However, the comparison of the crystal structures of tubulin-DMEP (4′-demethylepipodophyllotoxin) and tubulin-podophyllotoxin suggests that the C-4 β-configuration does not show any disadvantage for tubulin binding. 8 For podophyllotoxin derivatives as topoisomerase-II inhibitors, structure-activity relationship (SAR) data show that 4β-substitution is essential for the anticancer activity. 9, 10 In the attempt to discover less toxic and more effective anticancer agents, many podophyllotoxin derivatives have been synthesized for biological studies.
11,12 4β-1,2,3-Triazole derivatives of podophyllotoxin have been shown to exhibit more potent anticancer activity and better binding to topoisomerase-II than etoposide. [13] [14] [15] Recently, we also reported a group of podophyllotoxin glycoconjugates linked via 4β-1,2,3-triazole functionality as potential antitumor agents. [16] [17] [18] Our studies showed that podophyllotoxin derivatives with a perbutyrylated sugar residue displayed higher activity than their counterparts lacking butyryl groups. 16, 17 There have also been reports on the synthesis of dimeric podophyllotoxin derivatives 19, 20 which exhibited promising in vitro anticancer activity against different human tumour cell lines. In the present study, a group of dimeric podophyllotoxin derivatives 4 ( Figure 1 ), with different linkers have been prepared using the Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC) reaction. 21, 22 Their synthesis and anticancer activity against five cancer cell lines are described.
Results and discussion chemical synthesis
The click reaction of copper(I)-catalyzed Huisgen 1,3-dipolar azide-alkyne cycloaddition (CuAAC) provides 1,4-disubstituted 1,2,3-triazoles, which is a powerful tool for the generation of novel pharmacophores. 21, 22 To access dimeric podophyllotoxin derivatives 4 ( Figure 1 ), di-propargyl functionized linkers are required. Scheme 1 depicts the synthesis of symmetric 1,3-di-O-propargyl glycerol (10) and its glycosylated derivatives (12) (13) (14) . Initially, we tried direct propargylation of glycerol with propargyl bromide in the presence of sodium hydride (NaH) to prepare 10. However, the reaction provided complicated products and the strategy was abandoned. Thus, Solketal 5 was treated with propargyl bromide and sodium hydride, and then with HCl in methanol solution to give diol 6 as previously described. 23 The diol 6 was first converted to bissilyl ether 7 by treatment with tert-butyldimethylsilyl chloride (TBSCl) and imidazole in anhydrous N,N-dimethylformamide (DMF). The more labile primary TBS ether in 7 was then 
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synthesis and anticancer activity of dimeric podophyllotoxin derivatives selectively cleaved with pyridine-HF in pyridine. 24 Etherification of the primary alcohol 8 with propargyl bromide gave nine in 56% yield. Treatment of 9 with tetrabutylammonium fluoride (TBAF) in tetrahydrofuran (THF) gave alcohol 10. 25 Next, 10 was allowed to react with the α-glucose trichloroacetimidate derivative 11 26 in the presence of BF 3 ⋅Et 2 O at -78°C to provide, as expected, only the β-glycoside 12 in 63% yield. Then, removal of acetyl groups with CH 3 ONa in CH 3 OH produced 13, which was subjected to perbutyrylation with butyric anhydride in the presence of pyridine to give the perbutyrylated product 14 in good yield. Interestingly, the anomeric proton of the glucose residue was found significantly downfield and shifted in the 1 H-NMR spectra of the peracetylated derivative 12 (δ 6.45 ppm, d, J=8.0 Hz) and perbubyrylated derivative 14 (δ 6.14 ppm, d, J=8.0 Hz), while it appears to be normal in non-acylated 13 (δ 4.35 ppm, d, J=8.0 Hz). The coupling constant of 8.0 Hz for the anomeric proton confirms a β-glycosidic linkage in 12-14.
The synthesis of dipropargyl functionalized linkers based on glucose scaffold is described in Scheme 2. The readily available 6-O-tritylated 15 27 was treated with TBSCl and imidazole in anhydrous DMF to yield 16 in 80% yield. Acid catalyzed removal of the trityl group yielded 17 in 93% yield. Compound 17 was then treated with propargyl bromide and NaH to provide 18 (50%), which was treated with TBAF in the presence of acetic acid in THF to give triol 19 in 80% yield. Compound 19 was then subjected to benzylation, acetylation, or butyrylation by treatment with benzyl bromide/NaH, acetic anhydride/pyridine, or butyric anhydride/pyridine, respectively, to give 20, 21, or 22 in good to excellent yield.
The azido-substituted podophyllotoxin derivatives needed for the click reaction, 4β-azido-4-deoxypodophyllotoxin 23 and 4β-azido-4-deoxy-4′-demethylpodophyllotoxin 24, can be readily prepared from podophyllotoxin according to a previous report. 28 The azides 23 and 24 were allowed to react with dipropargyl functionalized linkers 10, 12-14, and 19-22 in the presence of CuSO 4 ⋅5H 2 O, sodium ascorbate in t-butyl alcohol and water (1:1) at room temperature to obtain symmetric (25) (26) (27) (28) (29) (30) (31) (32) and unsymmetric (33) (34) (35) (36) (37) (38) (39) (40) dimeric podophyllotoxin derivatives in very good yield (Scheme 3).
All the products were characterized by 1 H-NMR, 13 C-NMR, ESI-MS, and HRESI-MS data. The presence of the triazole ring in these dimeric podophyllotoxin derivatives 
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Zi et al was confirmed by the proton signal at around δ 7.27-7.96 ppm (C 5 -H of the triazole ring) in the aromatic region of the 1 H-NMR spectrum, as well as by a pair of carbon signals at around 145 ppm and 124 ppm in the 13 C-NMR spectrum. The proton at C-4 of the podophyllotoxin scaffold of these derivatives appears to be doublet at 5.85-6.22 ppm, typically having J 3,4 ,5.0 Hz due to a cis relationship between H-3 and H-4. The two podophyllotoxin moieties in symmetric dimeric derivatives (25) (26) (27) (28) (29) (30) (31) (32) The data in Table 1 indicate that the linking spacer between the two podophyllotoxin moieties can largely affect the activity of these compounds. Compound 29 which carries a perbutyrylated glucose residue displays much higher potency than those lacking a glucose residue (25) , having a free glucose residue (27) or having a peracetylated glucose residue (28) . This observation agrees with our earlier reports that several podophyllotoxin glycoconjugates containing perbutyrylated sugar residues show higher anticancer activity than those without butyryl groups. 16, 17 In comparison to 29, the 4′-demethylated analog 32 loses its activity, confirming the earlier observation that the substitution group on the 4′-position of podophyllotoxin scaffold can significantly affect the anticancer potency of podophyllotoxin derivatives. 29 Previously, we reported several groups of monomeric podophyllotoxin derivatives bearing similar structure elements as those dimeric ones in the present study. 16, 17, 29 Some of those monomeric derivatives show good anticancer activity with IC 50 values in low μM range. Since most of the dimeric podophyllotoxin derivatives in this study display weak anticancer activity, dimerization might not be a good strategy for improving the potency of podophyllotoxin derivatives.
One major drawback of cancer chemotherapy is associated with the low-/non-selective nature of cytotoxic drugs, which attack cancer cells as well as normal cells, leading to serious side effects. To evaluate the degree of selectivity of 29, its growth inhibitory effect on a normal human bronchial epithelial cell line, BEAS-2B, was measured ( Table 1) . The selectivity index (SI) was expressed as the ratio of the IC 50 value of the compound in normal BEAS-2B cell line over that in cancer cell line. 30, 31 A greater SI value indicates that the drug molecule displays higher selectivity towards cancer cells as compared with normal cells. As shown in Table 2 , compound 29 has SI values ranging from 4.4 to 35.7 in all five cancer cell lines texted. Literature papers have considered that an SI value greater than 2.0 32 or 3.0 33 is an interesting selectivity index. Importantly, the selectivity indexes of 29 are much greater than those observed for both clinically used anticancer drugs, etoposide and cisplatin, 
Conclusion
This paper describes the preparation of a group of dimeric podophyllotoxin derivatives linked via 1,2,3-triazole functional groups. 4β-Azido-podophyllotoxin/4′-demethylpodophyllotoxin reacts with various dipropargyl functionalized linkers by copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) reaction to produce novel dimeric podophyllotoxin derivatives. MTT assay was used to evaluate the in vitro anticancer activity of these compounds against a panel of five human cancer cell lines including HL-60 (leukemia), SMMC-7721 (hepatoma), A-549 (lung cancer), MCF-7 (breast cancer), and SW480 (colon cancer). Most of the synthesized compounds do not show anticancer activity. Notably, compound 29, which bears a perbutyrylated glucose residue on the glycerol linker and is 4′-O-methylated on the E ring, is highly active against all five tested cancer cell lines with IC 50 values ranging from 0.43 to 3.50 μM. As compared with the normal BEAS-2B (lung) cell line, compound 29 is significantly more selective towards all five tested cancer cell lines with selectivity indexes in the range of 4.4-35.7. Taken together, compound 29 is significantly more cytotoxic and selective towards cancer cells than the clinically used drug etoposide or cisplatin. Further studies are required to study the promising antitumor agent.
Experimental general
Melting points were uncorrected. Mass spectroscopy (MS) data were obtained in the ESI mode using API Qstar Pulsar instrument. HRMS data were obtained in the ESI mode using LCMS-IT-TOF (Shimadzu, Kyoto, Japan). NMR spectra were acquired using Bruker AV-400 or DRX-500 or Bruker AVANCE III-600 (Bruker BioSpin GmbH, Rheinstetten, Germany) instruments, where tetramethylsilane (TMS) was used as an internal standard. Column chromatography (CC) was performed with flash silica gel (200-300 mesh; Qingdao Makall Group Co., Ltd; Qingdao; China). All reactions were monitored by thin-layer chromatography (TLC) and spots were visualized by spraying 10% H 2 SO 4 in ethanol (EtOH) on warm silica gel plates. The human cancer cell lines HL-60, SMMC-7721, A-549, MCF-7, and SW480, and the normal BEAS-2B cell line were purchased from the American Type Culture Collection (ATCC).
Imidazole (3.8 g, 55.2 mmol) and TBSCl (7.2 g, 47.8 mmol) were added to a solution of diol 6 (2.4 g, 18.5 mmol) in dimethylformamide (DMF) (60 mL). The reaction mixture was stirred overnight, and then diluted with H 2 O (300 mL). The solution was extracted with ether (Et 2 O) (3×150 mL) and the combined organic layer was dried over sodium sulfate (Na 2 SO 4 ). After removing the solvent in vacuo, the residue was purified by CC (Rf=0.20, petroleum ether: ethyl acetate=40:1) to give 7 (5.2 g, 80%) as a colorless oil. 
To a solution of 7 (6.8 g, 19.0 mmol) in dry THF (60 mL), the HF⋅pyridine complex (1.7 mL) and pyridine (10 mL) were added. The reaction mixture was stirred for 20 hours. After completion of the reaction (TLC monitoring), the solution was diluted with diethyl ether (100 mL), washed with 0.5 M HCl (2×50 mL) and saturated copper sulfate solution (50 mL), and dried over anhydrous Na 2 SO 4 . After removal of the solvents, the residue was purified by chromatography (Rf=0.50, petroleum ether: ethyl acetate=4:1) to give 8 (3.4 g, 74%) as a colorless liquid. + 267 and found to be 267. A solution of BF 3 ⋅Et 2 O (87.2 μL, 0.7 mmol) in dichloromethane (1 mL) at -78°C was added dropwise to a solution of 11 26 (225 mg, 0.5 mmol) and 10 (77 mg, 0.5 mmol) in dry CH 2 Cl 2 (2 mL). The reaction mixture was brought to room temperature and stirred for 1 hour, and then Et 3 N (0.1 mL) was added to the mixture, followed by addition of AcOH (0.1 mL). The solvent was evaporated and the residue was purified by CC (Rf=0.60, petroleum ether: ethyl acetate=1:1) to obtain 12 (143.7 mg, 63%). 
1,3-Di-(prop-2-yn-1-yloxy)prop-2-yl 2,3,4,6-tetra-O-butyryl-β-Dglucopyranoside (14)
Butyric anhydride (0.3 mL, 2 mmol) was added to a solution of 13 (66.0 mg, 0.2 mmol) in pyridine (2 mL) at 0°C. The reaction mixture was stirred for 12 hours and then was diluted with water (5 mL) and extracted with ethyl acetate (3×5 mL). The organic layer was washed with 10% aqueous hydrochloric acid (10 mL) and brine (10 mL). The organic layer was dried over magnesium sulfate and evaporated to give a residue, which was purified by CC (Rf=0.20, petroleum ether: ethyl acetate=9:1) to obtain 14 (109.8 mg, 90% 
Prop-2-yn-1-yl 2,3,4-tri-O-tertbutyldimethylsilyl-β-D-glucopyranoside (17)
A solution of formic acid in ether (30 mL: 30 mL) was added dropwise to a solution of 16 (1.2 g, 1.5 mmol) in diethyl ether (30 mL) at room temperature. The mixture was stirred for 3 hours, then diluted with water (30 mL), and quenched via careful addition of solid potassium carbonate (K 2 CO 3 ). The layers were separated, and the aqueous layer was extracted with Et 2 O (3×30 mL), and the resulting organic layers were combined and concentrated in vacuo. 
Prop-2-yn-1-yl 6-O-(prop-2-yn-1-yl)-β-Dglucopyranoside (19)
To a solution of 18 (119.7 mg, 0.2 mmol) in dry THF (5 mL), TBAF (0.2 mL, 0.7 mmol) was added at room temperature. The mixture was stirred for 18 hours, and then the solvent was evaporated under reduced pressure and the crude product was purified by CC (Rf=0.50, CHCl 3 : CH 3 OH=20:1) to obtain the desired product 19 (41.0 mg, 80%) as a colorless syrup. 89 (m, 1 H) Prop-2-yn-1-yl 6-O-(prop-2-yn-1-yl)-2,3,4-tri-O-benzyl-β-D-glucopyranoside (20) Suspension (60%) of NaH in paraffin (28.0 mg, 0.7 mmol) was added to a solution of 19 (51.2 mg, 0.2 mmol) in anhydrous DMF (3 mL) at 0°C under argon atmosphere. The resulting solution was stirred for 30 minutes at room temperature. Benzyl bromide (0.2 mL, 1.1 mmol) was added drop-wise at 0°C followed by a catalytic amount of tetra-n-butyl ammonium iodide (20 mg). The resulting reaction mixture was stirred at room temperature under argon for 10 hours. After completion of the reaction (as judged by TLC), excess NaH was quenched with methanol (0.5 mL) followed by ice water (10 mL) and extracted with ether (3×10 mL). The combined organic layer was washed with water, brine, dried over anhydrous Na 2 SO 4 and concentrated in vacuo. The crude residue was purified by CC (Rf=0.20, petroleum ether: ethyl acetate=30:1) to obtain 20 (73.6 mg, 70%). 
To a solution of 20 (51.2 mg, 0.2 mmol) in pyridine (2 mL) at 0°C, acetic anhydride (0.2 mL, 2 mmol) was added. The reaction mixture was stirred at room temperature for 12 hours (TLC monitoring). The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (3×10 mL). The organic layer was washed with 10% aqueous hydrochloric acid (10 mL) and brine (10 mL). The organic layer was dried over Na 2 SO 4 and evaporated to give a residue, which was purified by CC (Rf=0.20, petroleum ether: ethyl acetate=4:1) to obtain 21 (69.5 mg, 91% 
Butyryl anhydride (0.3 mL, 2 mmol) was added to a solution of 20 (51.2 mg, 0.2 mmol) in pyridine (2 mL) at 0°C. The reaction mixture was stirred at room temperature for 12 hours. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (3×10 mL). The organic layer was washed with 10% aqueous hydrochloric acid (10 mL) and brine (10 mL). The organic layer was dried over Na 2 SO 4 and evaporated to give a residue, which was purified by CC (Rf=0.20, petroleum ether: ethyl acetate=10:1) to obtain 22 (86.7 mg, 93%). 
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Zi et al mixture was diluted with water (10 mL) and extracted with ethyl acetate (3×10 mL), and the combined organic layer was dried over Na 2 SO 4 . The solvent was evaporated and the residue was purified by CC to obtain the cycloaddition product. s, 6 H), 3.74 (s, 12 H), 3.65-3.52 (m, 9 H) 
